CGEN

#3444
Compugen Ltd
2.88 USD
+4.35%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
2.88
2.88
Годовой диапазон
1.23
2.88
Дневное изменение
+4.35%
Месячное изменение
+26.32%
6-месячное изменение
+38.46%
Годовое изменение
+121.54%
Предыдущее закрытие
2.76
Открыть
2.88
Bid
Ask
Минимум
2.88
High
2.88
Объем
8
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 272.31 M
  • Employee 75
  • Founded 1993
  • CEO Anat Cohen-Dayag
  • Website www.cgen.com
  • Headquarter Israel
  • FIGI UNKNOWN
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
4.03
Коэффициент цена/денежный поток
1.97

Compugen Ltd

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

Новости